Biotechnology and pharmaceutical companies frequently implement workforce reductions due to clinical trial setbacks, regulatory delays, or the continuous need to extend their operating cash runways. Because pre-revenue drug developers rely heavily on external funding, venture capital availability, and milestone achievements, any shift in macroeconomic market sentiment or higher capital costs forces management teams to prioritize core drug pipelines, pause non-essential research programs, and streamline overhead expenditures.